

REMARKS


Claims 13 and 14 were presented in the amendment filed July 28, 2008. In this supplemental Amendment, new claims 34-36 are added. These claims parallel claims 13, 14 and 33, now canceled, except that the new claims recite “a method for enhancing cytotoxic T cell activity toward PD-L1 or PD-L2 over-expressing cancer cells,. . . [in] a subject with cancer” as supported at least in the paragraph bridging pages 19-20 of the application as filed.

In rejecting claims 13-14 under 35 U.S.C. § 112, first paragraph, the Examiner states that the data in the specification “appears to indicate that anti PD-1 antibodies are capable of enhancing cytotoxic T cell activity toward PD-L1 overexpressing cells *in vivo*.” Office Action, page 3, second paragraph. Further, the Examiner invites Applicants to “amend the claims to recite a method for enhancing cytotoxic T cell activity toward PD-L1 overexpressing cells, wherein the subject has cancer” in order to overcome the rejection. Claims 34-36 are added to do this.

In view of the above and the Amendment filed July 25, 2008, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: August 13, 2008